Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
Investing.com - Anavex Life Sciences reported on Monday fourth quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Anavex Life Sciences announced earnings per share of $-0.18 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.17 on revenue of $0.00.
Anavex Life Sciences 's are down 39% and is trading at $10.51 , still down 50.66% from its 52 week high of $21.30 set on Monday, November 29, 2021.
Anavex Life Sciences shares lost 11.61% to trade at $10.51 in intra-day trade the report.
Anavex Life Sciences follows other major Healthcare sector earnings this month
Anavex Life Sciences's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, EPS of $1.91 on revenue of $6.91B.
Pfizer had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.78 on revenue of $22.6B, for EPS of $1.44 on revenue of $21.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar